A highly selective and sensitive competitive aptasensor capable of quantifying thrombin elevated with side effects in...

Area of Science:

• Biochemistry
• Analytical Chemistry
• Biomedical Engineering

Background:

• Blood clots are a critical complication in severe COVID-19.
• Accurate quantification of thrombin is essential for managing thrombotic events.
• Existing detection methods may lack the required sensitivity or selectivity.

Purpose of the Study:

• To develop a highly selective and sensitive biosensor for quantifying trace levels of thrombin.
• To utilize a DNA aptamer (TBA) and its complementary strand for thrombin detection.
• To establish a chemiluminescence-based assay for enhanced signal generation.

Main Methods:

• A label-free aptasensor was designed using a DNA aptamer (TBA) specific to thrombin.
• The assay relies on the differential formation of dsDNA and G-quadruplex structures.
• 1,1'-oxalyldiimidazole chemiluminescence (ODI-CL) with SFC green was employed for signal detection.

Main Results:

• The biosensor demonstrated a linear calibration curve for thrombin detection in the range of 10-320 mU/ml.
• A low limit of detection (LOD) of 3 mU/ml (43 pM) was achieved.
• The assay showed high accuracy, precision, and reliability in quantifying thrombin.

Conclusions:

• The developed aptasensor provides a sensitive and selective method for thrombin quantification.
• This technology holds potential for monitoring and managing thrombotic risks in severe COVID-19 patients.
• The label-free, chemiluminescence-based approach offers a promising diagnostic tool.